A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 29, 2020

Primary Completion Date

May 19, 2021

Study Completion Date

May 19, 2021

Conditions

Guillain-Barré Syndrome

Interventions

DRUG

ANX005

investigational drug

DRUG

Intravenous immunoglobulin

investigational drug

Trial Locations (2)

National Institute of Neurosciences and Hospital, Dhaka

Aarhus University Hospital, Aarhus

All Listed Sponsors

collaborator

ResearchPoint Global

OTHER

collaborator

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

lead

Annexon, Inc.

INDUSTRY

NCT04035135 - A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) | Biotech Hunter | Biotech Hunter